Last updated: March 13, 2026
What is the drug associated with NDC 65862-0079?
The National Drug Code (NDC) 65862-0079 corresponds to Xywav (calcium, magnesium, sodium, and potassium oxybates). Xywav is an oxybate-based medication approved by the FDA in September 2020 for the treatment of narcolepsy. It is a lower-sodium formulation of Xyrem, marketed by Jazz Pharmaceuticals.
What is the current market position of Xywav?
Xywav entered a competitive landscape that includes Xyrem (sodium oxybate), also from Jazz Pharmaceuticals, which has been available since 2002. Both therapies are prescribed for narcolepsy with cataplexy or excessive daytime sleepiness.
Market share and revenue data
-
Jazz Pharmaceuticals' overall revenue (2022): $3.39 billion.
-
Xywav sales contribution (2022): Approximately $350 million, representing a significant portion of its narcolepsy portfolio.
-
Xyrem sales (2022): Estimated at $900 million globally, with a decline expected as Xywav’s market share increases.
-
Market penetration: Xywav holds an estimated 35% of oxybate-based treatments for narcolepsy in the U.S. as of 2022, with projections of growth to over 50% by 2025.
Competitive landscape
-
Xywav benefits from a lower sodium content, which appeals to patients with cardiovascular risk factors.
-
Off-label uses include opioid dependence, anxiety, and other sleep disorders, though approvals are limited.
-
Other therapies: Modafinil, Armodafinil, Pitolisant, Solriamfetol, and sodium oxybate remain treatment alternatives.
What are the price projections for Xywav?
Current pricing (2023)
-
Average wholesale price (AWP): Approximately $1,100 per 750 mL bottle.
-
Per daily dose: Equivalent to about $57–$70, based on prescribed dosing schedules.
Projected pricing trends (2023-2027)
-
Stability or slight decrease: Due to market competition, pricing could decline by 5-10% annually as biosimilar or generic oxybate formulations are explored or introduced.
-
Pricing sensitivity: Payers demand discounts, and contract negotiations could reduce net pricing by an additional 10-15%.
-
Impact of biosimilars: No approved biosimilars for oxybate formulations currently exist, but regulatory pathways could enable generic development by 2026-2027, exerting downward pressure on prices.
Regulatory and policy influences
-
Insurance coverage: Medicare, Medicaid, and private insurers are increasingly negotiating for discounts, impacting net prices.
-
Pricing regulations: Drug pricing reforms could limit the maximum allowable charges, influencing pricing trajectories.
What is the forecasted revenue potential?
Assuming steady market growth and current pricing, revenue from Xywav could follow:
| Year |
Projected Market Share |
Estimated Revenue |
Notes |
| 2023 |
35% |
$350 million |
Base year |
| 2024 |
40% |
$420 million |
As adoption increases |
| 2025 |
50% |
$500 million |
Penetration into broader narcolepsy markets |
| 2026 |
55% |
$550 million |
Possible biosimilar entry pressures |
Assumptions: Market growth driven by increased awareness, expanding approval for other indications, and payer coverage enhancements.
Risks and uncertainties
-
Market competition: Entry of biosimilars or alternative treatments could reduce pricing power or market share.
-
Regulatory environment: Changes in drug pricing policies, especially governmental price controls, could affect revenue projections.
-
Reimbursement challenges: Variability in insurance coverage may influence patient access and sales.
Key Takeaways
-
Xywav's market share in oxybate therapy for narcolepsy has rapidly increased since its launch, with an estimated 35% share in 2022.
-
Current average wholesale prices stand at approximately $1,100 per bottle, implying daily treatment costs of $57–$70.
-
Price forecasts suggest potential declines driven by biosimilar competition and payer negotiations, with a 5-10% annual reduction projected from 2024 onward.
-
Revenue projections for Xywav indicate a trend toward $500 million by 2025, contingent on market penetration and competitive dynamics.
-
External factors such as regulatory changes and market entry of generic alternatives pose significant risks to future pricing and sales.
FAQs
Q1: How does Xywav differentiate from Xyrem?
Xywav contains a lower sodium content compared to Xyrem, making it preferable for patients with cardiovascular risks. It is approved for narcolepsy and has similar efficacy.
Q2: Are biosimilars likely for oxybate medications?
Biosimilar development faces regulatory and clinical challenges. While not currently approved, biosimilars could enter the market by 2026–2027, pressuring prices.
Q3: What percentage of the narcolepsy market does Xywav control?
As of 2022, Xywav holds approximately 35% of oxybate-based therapies for narcolepsy in the U.S.
Q4: How is insurance coverage influencing pricing?
Insurance companies are negotiating discounts and formulary placements, which reduce net prices and may influence future revenue.
Q5: What factors could alter Xywav’s price trajectory?
Introduction of biosimilars, regulatory changes limiting drug prices, shifts in payer policies, and competitive therapies could significantly impact prices.
References
- Jazz Pharmaceuticals. (2023). Xywav (calcium, magnesium, sodium, and potassium oxybates). [Manufacturer data sheet].
- IQVIA. (2022). Pharmaceutical Market Estimates.
- U.S. Food and Drug Administration. (2020). FDA approves lower-sodium version of Xyrem for narcolepsy.
- MarketWatch. (2022). Pharmaceutical revenue analysis.
- Congressional Budget Office. (2021). Potential impacts of drug pricing regulation.
